US 12,343,347 B2
Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
Allen B. Reitz, Lansdale, PA (US); and Garry Robert Smith, Royersford, PA (US)
Assigned to Biohaven Therapeutics Ltd., Tortola (VG)
Filed by Biohaven Pharmaceutical Holding Company Ltd., New Haven, CT (US)
Filed on Nov. 16, 2021, as Appl. No. 17/527,428.
Application 17/527,428 is a division of application No. 16/518,008, filed on Jul. 22, 2019, granted, now 11,197,864, issued on Dec. 14, 2021.
Application 16/518,008 is a division of application No. 14/410,647, granted, now 10,357,497, issued on Jul. 23, 2019, previously published as PCT/US2013/047315, filed on Jun. 24, 2013.
Claims priority of provisional application 61/663,573, filed on Jun. 23, 2012.
Prior Publication US 2022/0072006 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/428 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01)
CPC A61K 31/541 (2013.01) [A61K 31/428 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01)] 3 Claims
 
1. A method for treating a non-proliferative disease in which riluzole is clinically relevant, said method comprising administering to a subject an effective amount of at least one compound of the formula (II):

OG Complex Work Unit Chemistry
including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
R12a, R12b, R12c, R12d, and R12e are each independently selected from the group consisting of hydrogen, deuterium, halogen, trifluoromethyl, trifluoromethoxy, optionally substituted C1-C6 alkyl, and optionally substituted C1-C6 alkoxy.